NCT07349160 is a EARLY_PHASE1 clinical trial of Metabolically Armed TIL cells. in Advanced Solid Tumors, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Who is sponsoring NCT07349160?

NCT07349160 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What drugs are being tested in NCT07349160?

Interventions in NCT07349160: Metabolically Armed TIL cells..

What condition does NCT07349160 study?

NCT07349160 studies Advanced Solid Tumors.

Is NCT07349160 still recruiting?

NCT07349160 is currently recruiting now. Last updated 16 January 2026.

Last reviewed 2026-01-16 · How we verify

NCT07349160

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

Recruiting now EARLY_PHASE1 Last updated 16 January 2026

What this trial tests

EARLY_PHASE1 trial testing Metabolically Armed TIL cells. in Advanced Solid Tumors in 36 participants. Currently enrolling.

Timeline

10 January 2026

Primary endpoint
15 March 2027

20 January 2028

Quick facts

Lead sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	10 January 2026
Primary completion	15 March 2027
Estimated completion	20 January 2028
Sites	1 location across China

Drugs / interventions tested

Metabolically Armed TIL cells.

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

Adults 19 to 70, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

HosTIL territory: mapping the landscape of toxicity in TIL therapy.
Woodford R, Demiguelarroyo MJ, Jethra R, Lorigan PC, et al · · 2026 · PMID 41956543 · DOI 10.1136/jitc-2025-014378

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07349160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Last refreshed: 16 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07349160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing